SWOG clinical trial number
SWOG-8733
Evaluations of Operable Bladder Cancer Patients with Pre-Operative Irradiation + 5-FU and Inoperable Patients With Irradiation + 5-FU Alone, Phase II, A Pilot Study for Patients Ineligible for SWOG-8710
Closed
Phase
Accrual
77%
Published
Abbreviated Title
Local Bladder
Activated
04/01/1988
Closed
02/15/1997
Research committees
Genitourinary Cancer
Publication Information Expand/Collapse
2008
Treatment options for muscle invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, adriamycin, and cisplatin: report of Southwest Oncology Group trial 8733 [PMID18404692]
Other Clinical Trials
SWOG Clinical Trial Number
S2312
A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2210
S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
S2200
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
14%
Open
Phase